Navigation Links
Hebrew University research leads to advanced trials of new cancer treatment
Date:6/15/2009

Jerusalem, June 14, 2009 Research by a Hebrew University of Jerusalem professor has led to the development of a product that has been shown in clinical trials to be successful in halting the growth of various types of cancer cells.

The research, conducted by Prof. Avraham Hochberg of the Silberman Institute of Life Sciences at the university, has won for him first prize among faculty members for this year's Kaye Innovations Awards, which was presented on June 9 during the annual Hebrew University Board of Governors meeting.

Prof. Hochberg was successful in isolating the H19 gene in humans and determining that it is significantly expressed in over 33 different forms of cancer, including superficial bladder carcinoma and pancreatic, ovarian and metastatic liver cancer, while laying dormant and non-expressed in non-cancerous cells.

Research has also demonstrated that the H19 gene plays a significant role in the tumor development process by enabling tumor cells to survive under stress conditions, such as low serum and low oxygen levels, that are typical conditions of the environment in which cancerous cells develop. This survival supports the growth of the tumor and the development of metastases.

The research and understanding of the origin of cancer and metastases has progressed significantly in recent years. In light of scientific breakthroughs in cancer research, and the role of the H19 gene in such processes, it is believed that an anti-cancer drug based on suppressing the expression of the H19 gene has the potential to provide benefits that are competitive with existing treatment methods.

Prof. Hochberg's research was patented by Yissum Research Development Company of the Hebrew University. In 2005 Yissum established BioCancell Inc., to which it licensed the technology. The company is now traded in the Tel Aviv stock exchange (TASE). BioCancell's leading product, BC-819, has demonstrated efficacy in clinical trials (now in an advanced stage) in Israel and the US for the treatment of human bladder, pancreatic and ovarian cancers.


'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert  

Related medicine news :

1. Safe Playground to be Built at Politz Hebrew Academy
2. Groundbreaking for Safe Playground Build at Politz Hebrew Academy
3. Hebrew University scientist develop technique for eliminating reblockage of arteries
4. Hebrew University scientists succeed through stem cell therapy in reversing brain birth defects
5. Event Honoring Bill Gates Raises Over $1.5 Million for Sustainable Agriculture Research at The Hebrew University of Jerusalem
6. The Connecticut Hospice, Inc. Announces the Arrival of Six Nurse Scholars From The Henrietta Szold-Hadassah-Hebrew University School of Nursing
7. RNA engineering to combat series of illnesses wins Kaye Award for Hebrew University dean
8. Hebrew University research on octopuses sheds light on memory
9. Humans have more distinctive hearing than animals, Hebrew U study shows
10. Robert H. Smith Feeding the Future with $15 Million Gift to Hebrew University of Jerusalem
11. Hebrew SeniorLife researcher finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hebrew University research leads to advanced trials of new cancer treatment
(Date:2/11/2016)... CA (PRWEB) , ... February 11, 2016 , ... ... extensive experience performing a wide range of cosmetic procedures. Along with performing procedures, ... the efficiency and results of many cosmetic procedures. One of the most common ...
(Date:2/11/2016)... ... February 11, 2016 , ... The Chartis Group, a ... five firms in the “2015/2016 Best in KLAS: Software and Services” report in ... a research and insights firm on a global mission to improve healthcare delivery ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, Inc. (AIS) ... A Case Study for Plans and Purchasers.” Executives from Intel Corp. and Providence ... on value-based health benefits program Connected Care, will discuss the challenges they faced ...
(Date:2/11/2016)... ... February 11, 2016 , ... Life is known for throwing ... 60 and older, who gather once a year to play softball to raise money ... the game, the more than 50 players who competed in this year’s softball tournament ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... communities with their ongoing community involvement program, introduces a new charity campaign to ... children, donations are now being accepted at https://donate.rmhc.org/ . , Ronald McDonald ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions ... Transformational M&A achieved through NPS and Dyax acquisitions and the ... M&A achieved through NPS and Dyax acquisitions and the announced ... with most robust pipeline in Shire , s ... most robust pipeline in Shire , s history ...
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... ALBANY, New York , February 11, 2016 ... Research announces the release of a new research report, titled ... Growth, Trends and Forecast, 2013 - 2019". According to the ... expand at a 4.40% CAGR from 2013 to 2019, growing ... bn by 2019. --> --> ...
Breaking Medicine Technology: